Category: Prostate Cancer Detection

When something could save lives, having an abundance of it on hand is a good thing. On the other hand, if there’s a scarcity of it, it won’t be readily available when it’s needed—and many lives will be put at risk. This is true for a prostate cancer (PCa) imaging agent called Gallium-68 (68Ga or keep reading

Contrary to popular belief, a new study says you’re never too old to get high-risk prostate cancer (PCa). There’s been a recent trend to cut back on PSA screening for men over age 70. It wasn’t that long ago when such organizations as the American Urological Society and the American Society of Clinical Oncology promoted keep reading

The blog below about PI-RADS v1.0, predated a revision, PI-RADS v2.0 by a year. Four years later another revision, PI-RADS v2.1, offered more specific descriptions and definitions in order to improve agreement among readers. Recent studies tested PI-RADS v2.1 compared with v2.0. keep reading

Did your doctor say it’s time for a biopsy, based on your PSA results? Do you shudder at the idea? How do you know you really need to have 12+ randomly placed needles throughout your prostate gland? The answers to these questions can be found in a Swedish paper published online July 9, 2021 by keep reading

Imagine this scenario. Your doctor orders a pelvic CT scan to check if the pain you’re experiencing is due to a kidney stone or other blockage. After the scan, he says, “I’m happy to tell you there’s no evidence of stones and your kidney looks fine. Oh, and incidentally, you have prostate cancer.” Of course, keep reading

Fusion guided prostate biopsies are the new darling of urologic diagnostic procedures. For decades, the transrectal ultrasound (TRUS) guided 12-plus needle sampling of the gland was the prostate cancer (PCa) diagnostic gold standard, despite its widely recognized shortcoming: Inaccuracy rates of at least 30% on average Overdetecting insignificant PCa while often missing significant PCa Tends keep reading

At this year’s American Urological Association annual meeting in Orlando, FL, there were numerous courses that offer continuing education credits for physicians. One of the courses was directed by Dr. J. Stephen Jones who, for five years, served as Chair of the Urology Department at the Cleveland Clinic. He is very well respected in the keep reading

It’s been three years since the US Preventive Services Task Force issued a recommendation against routine PSA screening for prostate cancer in otherwise healthy men or men who were not at known risk for the disease. It was controversial then—and not much has changed. A multi-institution team published a research letter in the Journal of keep reading